BioLineRx (BLRX) Gross Margin (2024 - 2025)
BioLineRx's (BLRX) quarterly Gross Margin came in at 79.38% in Q4 2025, up 3121.0% year-on-year from 2.46% in Q4 2024, and down 1.18% quarter-over-quarter from 80.33% in Q3 2025.
BioLineRx (BLRX) Gross Margin (2024 - 2025) Analysis & Trends
BioLineRx's Gross Margin history runs 2 years deep, the most recent figure standing at 79.38% for Q4 2025.
- On a quarterly basis, Gross Margin rose 3121.0% year-over-year to 79.38% in Q4 2025; TTM through Dec 2025 was 80.51%, a 1252.0% increase from a year earlier, with the FY2025 full-year figure at 80.51%, up 1252.0% from the prior year.
- Gross Margin eased to 79.38% in Q4 2025 per BLRX's latest filing, from 80.33% in the prior quarter.
- Across five years, Gross Margin topped out at 86.67% in Q1 2025 and bottomed at 48.17% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 88.95% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | BioLineRx | 6.98 Bn | 6.98 Bn | 154,000.00 | 79.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 79.38% |
| Sep 30, 2025 | 80.33% |
| Jun 30, 2025 | 76.32% |
| Mar 31, 2025 | 86.67% |
| Dec 31, 2024 | 48.17% |
| Sep 30, 2024 | 83.37% |
| Jun 30, 2024 | 83.37% |
| Mar 31, 2024 | 78.77% |